About
Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment.
Parabilis Medicines, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:PBLS
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $29.04 | $30.19 | $27.44 | $29.19 | $29.19 | +0.15 | 557,000 |
| 2026-06-26 | $26.05 | $29.10 | $26.05 | $28.80 | $28.80 | +2.75 | 581,300 |
| 2026-06-25 | $27.32 | $27.99 | $25.70 | $26.36 | $26.36 | -0.96 | 1,043,400 |
| 2026-06-24 | $27.46 | $28.42 | $26.58 | $27.32 | $27.32 | -0.14 | 599,800 |
| 2026-06-23 | $26.51 | $28.28 | $26.23 | $27.51 | $27.51 | +1.00 | 627,900 |
| 2026-06-22 | $26.00 | $28.06 | $25.56 | $27.54 | $27.54 | +1.54 | 830,800 |
| 2026-06-18 | $25.98 | $27.00 | $25.35 | $25.85 | $25.85 | -0.13 | 685,100 |
| 2026-06-17 | $30.00 | $30.22 | $25.98 | $26.03 | $26.03 | -3.97 | 1,929,200 |
| 2026-06-16 | $25.26 | $26.72 | $24.91 | $26.59 | $26.59 | +1.33 | 3,384,300 |
| 2026-06-15 | $26.80 | $28.08 | $24.51 | $25.01 | $25.01 | -1.79 | 1,280,300 |
| 2026-06-12 | $29.86 | $32.47 | $26.88 | $27.26 | $27.26 | -2.60 | 1,035,500 |
| 2026-06-11 | $30.00 | $34.47 | $29.65 | $30.31 | $30.31 | +0.31 | 1,600,200 |
| 2026-06-10 | $33.35 | $34.02 | $26.61 | $31.60 | $31.60 | -1.75 | 5,496,700 |
| 2026-06-09 | $20.00 | $20.00 | $20.00 | $20.00 | $20.00 | 0.00 | 0 |
| 2026-06-08 | $20.00 | $20.00 | $20.00 | $20.00 | $20.00 | 0.00 | 0 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Jun 18, 2026 | Filing |
| 8-K | Jun 11, 2026 | Current Report |
| S-8 | Jun 10, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Jun 10, 2026 | Prospectus |
| FWP | Jun 10, 2026 | Free Writing Prospectus |
| EFFECT | Jun 9, 2026 | Notice of Effectiveness |
| S-1MEF | Jun 9, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Jun 9, 2026 | Certification by an exchange approving securities for listing |
| S-1/A | Jun 9, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| 8-A12B | Jun 5, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Mathai Mammen, M.D., Ph.D.
Chairman, Chief Executive Officer and President
Fawzi Benzaghou, M.D.
Chief Medical Officer
Helen Ho, Ph.D.
Chief Business and Strategy Officer
Thomas Kotarakos
Chief Financial Officer
Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Teresa Jurgensen, J.D.
General Counsel
Alexis Borisy
Director
Edward Fitzgerald
Director
Rick Klausner, M.D.
Director
Alan M. Sebulsky
Director
